Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.81
-0.44 (-3.32%)
At close: Apr 28, 2026, 4:00 PM EDT
13.06
+0.25 (1.95%)
After-hours: Apr 28, 2026, 5:48 PM EDT
Cullinan Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | - | - | 18.94 | |
| Gross Profit | - | - | - | - | 18.94 | |
| Selling, General & Admin | 54.25 | 54.02 | 42.49 | 40.19 | 29.15 | |
| Research & Development | 187.4 | 142.9 | 148.16 | 91.95 | 57.75 | |
| Operating Expenses | 241.65 | 196.92 | 190.65 | 132.14 | 86.9 | |
| Operating Income | -241.65 | -196.92 | -190.65 | -132.14 | -67.95 | |
| Interest & Investment Income | 22.21 | 29.66 | 21.63 | 6.61 | 0.48 | |
| Other Non Operating Income (Expenses) | -0.44 | -0.2 | 0.24 | 0.06 | -0.01 | |
| EBT Excluding Unusual Items | -219.88 | -167.46 | -168.78 | -125.47 | -67.49 | |
| Gain (Loss) on Sale of Assets | - | - | - | 276.79 | - | |
| Asset Writedown | - | - | -0.44 | - | - | |
| Pretax Income | -219.88 | -167.46 | -169.22 | 151.32 | -67.49 | |
| Income Tax Expense | - | 0.12 | -14.12 | 42.12 | - | |
| Earnings From Continuing Operations | -219.88 | -167.58 | -155.1 | 109.2 | -67.49 | |
| Minority Interest in Earnings | - | 0.19 | 1.94 | 2.02 | 1.92 | |
| Net Income | -219.88 | -167.38 | -153.16 | 111.21 | -65.57 | |
| Net Income to Common | -219.88 | -167.38 | -153.16 | 111.21 | -65.57 | |
| Shares Outstanding (Basic) | 59 | 54 | 42 | 45 | 43 | |
| Shares Outstanding (Diluted) | 59 | 54 | 42 | 47 | 43 | |
| Shares Change (YoY) | 9.82% | 29.41% | -10.91% | 8.27% | 116.61% | |
| EPS (Basic) | -3.72 | -3.11 | -3.69 | 2.46 | -1.52 | |
| EPS (Diluted) | -3.72 | -3.11 | -3.69 | 2.38 | -1.52 | |
| Free Cash Flow | -175.8 | -145.3 | -134.48 | -127.8 | -43.43 | |
| Free Cash Flow Per Share | -2.98 | -2.70 | -3.24 | -2.74 | -1.01 | |
| Gross Margin | - | - | - | - | 100.00% | |
| Operating Margin | - | - | - | - | -358.73% | |
| Profit Margin | - | - | - | - | -346.14% | |
| Free Cash Flow Margin | - | - | - | - | -229.28% | |
| EBITDA | -241.34 | -196.61 | -190.34 | -132.04 | -67.9 | |
| D&A For EBITDA | 0.31 | 0.31 | 0.31 | 0.09 | 0.05 | |
| EBIT | -241.65 | -196.92 | -190.65 | -132.14 | -67.95 | |
| Effective Tax Rate | - | - | - | 27.84% | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.